The End of a Controversy: The Rise, Fall, and Redemption of Paclitaxel-Coated Devices

Paclitaxel-coated devices (PCDs) for peripheral revascularization were initially considered one of the great success stories in endovascular treatment. Supported by more than a half dozen randomized trials, PCDs promised prolonged patency and decreased rates of target-lesion revascularization that had not been observed with non-coated devices.1,2 Once approved in the United States (US), PCDs became the most frequently used devices for femoropopliteal artery treatment and had a Class I indication in US guidelines.

Source: The American Journal of Cardiology - February 16, 2024 Category: Cardiology Authors: Eric A. Secemsky, Robert W. Yeh, Peter A. Schneider, William Gray, Sahil Parikh Tags: Editorial Source Type: research